The Pulmonx® solution for treatment of severe emphysema
- Accurately identifies appropriate patients
- The Chartis® System enables physicians to identify appropriate candidates for the Zephyr® Endobronchial Valve therapy
- Offers sustained and meaningful patient benefits
- The Zephyr valve provides a treatment option that significantly improves lung function, exercise tolerance, and quality of life in patients
with severe emphysema
- Cloud-based quantitative CT analysis
- The StratX™ analysis quantifies the completeness of each fissure using an algorithm that has been validated in a retrospective study of over 200 EBV patients, the largest
such analysis performed to date. Fissure completeness is a proven predictor for volume reduction resulting from EBV® therapy.
Learn more about products in development.